About the Company
ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ARDX News
Ardelyx, Inc. Reports Employment Inducement Grants
WALTHAM, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...
What's Going On With Ardelyx Stock After Earnings?
Ardelyx, Inc. (NASDAQ:ARDX) shares are moving Friday after the company reported its fourth-quarter financial results after the bell Thursday. Here's a look at what to know. What To Know ...
Ardelyx, Inc. (NASDAQ:ARDX) Q4 2023 Earnings Call Transcript
Ardelyx, Inc. (NASDAQ:ARDX) Q4 2023 Earnings Call Transcript February 22, 2024 Ardelyx, Inc. misses on earnings expectations. Reported EPS is $-0.12 EPS, expectations were $-0.09. Ardelyx ...
Ardelyx spikes as kidney patient bill advances in Congress
Ardelyx (ARDX) stock jumps as kidney disease bill progresses in Congress, easing concerns about the future of its oral ...
Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that ...
Ardelyx Inc
What Is a Registered Investment Advisor? RIAs aren't just for the wealthy anymore, and they have a fiduciary duty to put their clients' interests first.
Ardelyx Q4 Preview: Recent Bull Run May Pause While Market Digests 2024 Guidance
Ardelyx, Inc. shares have seen significant growth, up by 47% year-to-date and over 250% on a 5-year basis. The company markets and sells tenapanor, a drug approved for the treatment of Irritable ...
What's Going On With Ardelyx Stock After Earnings?
Wedbush analyst Laura Chico reiterates Ardelyx with an Outperform and maintains $13 price target. Ardelyx expects full-year 2024 U.S. net product sales revenue for Ibsrela to be between $140 ...
Ardelyx, Inc. Reports Employment Inducement Grants
ARDELYX, INC. - 8-K, Current Report 05.03. Ardelyx spikes as kidney patient bill advances in Congress 28.02. ARDELYX, INC. - S-8, Securities to be offered to employees in employee benefit plans 27.02.
Ardelyx, Inc.: Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that ...
Loading the latest forecasts...